One Study Changed How America Does Birth. Here's Why That's Complicated.

I

n 2018, a study published in the New England Journal of Medicine quietly shifted the landscape of obstetric care in the United States.

The study was called the ARRIVE trial — A Randomized Trial of Induction Versus Expectant Management — and its headline finding was striking: elective induction of labor at 39 weeks in low-risk, first-time pregnant people resulted in a lower cesarean rate than waiting for labor to begin on its own.

That finding landed in a health system that had been trying to reduce its cesarean rate for years. By 2022, elective induction at 39 weeks had become common clinical practice. Both ACOG and the Society for Maternal-Fetal Medicine issued statements that offering elective induction at 39 weeks was "a reasonable option" for low-risk, nulliparous pregnant people.

The rate of inductions in the U.S., already at about 30% of all births, continued to climb.

Here's the thing: the ARRIVE trial is a real study, with real data, and real findings worth taking seriously. It's also insufficient to justify the sweeping practice changes it's been used to support — and understanding why is important for anyone who supports or counsels pregnant people.

What the ARRIVE Trial Actually Found

The study enrolled 6,106 low-risk, first-time pregnant people at academic medical centers across the United States between 2014 and 2017. Half were randomly assigned to elective induction at 39 weeks; half were assigned to expectant management, meaning they waited for labor to begin spontaneously (or for a medical indication to develop, up to 40 weeks and 5 days).

The cesarean finding: The induction group had a cesarean rate of 18.6%, compared to 22.2% in the expectant management group. This was the principal secondary outcome of the study, and it was statistically significant.

The primary outcome: A composite of perinatal death and severe neonatal complications. The induction group had a rate of 4.3%, compared to 5.4% in the expectant management group. This difference showed a trend in favor of induction, but did not reach statistical significance.

In plain language: induction at 39 weeks appeared to lower the cesarean rate. It did not significantly change the rate of serious complications for babies — though there was a directional trend.

That's worth knowing. It's also not the whole picture.

The Limitations That Got Quietly Buried

Only 27% of eligible people participated.

Of the 22,533 people who were eligible for the ARRIVE trial, only 6,106 — about 27% — consented to randomization. The study tells us nothing about the other 73% who declined. Were they more likely to have strong birth preferences? More likely to prefer avoiding intervention? The study population may not represent low-risk pregnant people broadly.

It was conducted at academic medical centers.

The ARRIVE trial took place at a small number of large academic hospitals — settings with specialized staff, high-volume labor units, and resources that many community hospitals and birth centers don't have. The cesarean rates in the study (18–22%) were notably lower than the national average for similar populations, suggesting the study conditions weren't typical of where most people actually give birth.

When Ontario midwives analyzed the ARRIVE findings for their own practice context, they noted that nulliparous induction rates at Ontario hospitals were 31.4% — significantly higher than the 18.6% seen in the ARRIVE induction group. In their setting, induction appeared to increase cesarean risk, not decrease it.

"Low risk" was narrowly defined.

Participants had to meet a specific definition of low risk that excluded anyone with a condition considered an indication for delivery before 40 weeks and 5 days. They were also predominantly nulliparous (first-time pregnant) and younger, with a median age of 23–24. The results may not translate to multiparous people, older pregnant people, or those with more complex histories.

The cesarean rate was a secondary outcome.

The study's primary outcome — the composite of perinatal death and severe neonatal complications — did not reach statistical significance. The finding that's driven the practice change (lower cesarean rates) was actually a secondary outcome. This matters statistically: when you look at secondary outcomes rather than primary ones, the risk of finding a result by chance increases.

So Why Is It Driving Practice?

Reducing the cesarean rate is a legitimate and important public health goal. Cesarean sections carry real risks — longer recovery, increased risk of complications in future pregnancies, and for babies, some evidence of differences in microbiome colonization and immune development. Any intervention that might lower the cesarean rate gets attention.

The ARRIVE trial provided the first large-scale randomized controlled trial data on elective induction at 39 weeks. Before it, the prevailing assumption was that elective early induction increased cesarean risk. ARRIVE challenged that assumption with real data, and that's genuinely valuable.

But there's a gap between "this is valuable information that should inform individual conversations" and "this is sufficient justification for routine elective induction across all low-risk nulliparous pregnancies." The researchers themselves noted this in the original paper. Critics of widespread adoption, including international obstetric bodies, have flagged the external validity concerns.

The jump from a single trial — conducted in a narrow population, in specific settings, with self-selected participants — to routine clinical practice happened faster than the evidence warranted.

What This Means for Doulas and Birth Workers

Birth workers aren't in the room to tell clients whether to accept or decline an induction. But they are in a position to help clients understand what they're being told — and what questions to ask.

When the ARRIVE trial comes up (and it will — providers cite it regularly), here are the things worth knowing:

The study found that elective induction at 39 weeks can lower cesarean rates — in first-time pregnant people, in well-resourced academic settings, among those willing to be randomized. Whether those findings apply to the specific person in front of you depends on their demographics, their provider's institution, their cervical readiness, and their own values and preferences.

There is no universal right answer. There is an informed conversation to be had.

A doula who understands the nuance of the ARRIVE trial can help a client ask: "Does this apply to me? What is the cesarean rate at this hospital? What would expectant management actually look like for my situation?"

That's not anti-medicine. That's what informed consent is supposed to look like.

The Bigger Picture

Birth doesn't happen in a vacuum. It happens in systems — with resources, pressures, scheduling constraints, liability concerns, and population-level data that sometimes gets applied to individuals without enough translation.

The ARRIVE trial is a good example of how science moves through those systems: a real study, with real findings, that got amplified past what the evidence could fully support — not out of bad faith, but because the finding answered a question people desperately wanted answered.

Birth workers who understand this are better equipped to support people through it. Not to undermine their providers. To help them participate.

This post is part of BirthPro's Monday Night Mentoring series. The June 8 session covers Interventions and Induction — bring a question, a scenario, or a hot take about the ARRIVE trial. This is exactly the kind of evidence we need to be able to talk about intelligently.

Interested in birth worker training? Visit birthpro.org.